Molecular Docking Workflows for Veterinary Antiparasitic Screening: A Computational Framework for Target Identification and Inhibitor Prioritization

The global burden of parasitic infections in domestic animals and livestock drives an ongoing need for novel antiparasitic agents. Resistance to existing chemotherapeutics, coupled with toxicity and cost constraints, has accelerated the adoption of computational approaches in veterinary drug discovery [1, 2]. Molecular docking, when embedded in structured workflows that integrate structural biology, biophysical chemistry, and bioinformatics, provides a systematic pipeline for identifying and prioritizing candidate inhibitors against validated parasite protein targets. This article presents a comprehensive framework for molecular docking workflows tailored to veterinary antiparasitic screening, drawing on recent studies of helminth, protozoan, and apicomplexan parasites.

Core Components of Molecular Docking Workflows

A canonical docking workflow for veterinary antiparasitic screening comprises six sequential stages: target selection and structural modeling, binding site mapping, compound library preparation, molecular docking and scoring, ADMET (absorption, distribution, metabolism, excretion, toxicity) filtering, and post-docking validation through molecular dynamics (MD) simulations. Each stage introduces specific computational choices that influence the reliability and translational potential of the predicted inhibitors.

Target Selection and Structural Modeling

The choice of molecular target is guided by essentiality in parasite survival, absence of close mammalian orthologs to minimize off-target effects, and druggability of the active site. For helminths, detoxification enzymes such as glutathione S-transferases (GSTs) are promising targets because they neutralize xenobiotics and manage oxidative stress in the parasite [3]. For protozoan Leishmania species, trypanothione reductase (TryR) and glycerol-3-phosphate dehydrogenase (GPDH) serve critical roles in redox homeostasis and energy metabolism [1]. In apicomplexan parasites like Theileria annulata, epigenetic regulators including histone deacetylases (HDACs), SET domain methyltransferases, and protein arginine methyltransferases (PRMTs) present alternative targets [2].

When an experimentally determined three-dimensional structure is unavailable, homology modeling or deep learning-based prediction is employed. The AlphaFold algorithm has been used to generate the structure of the mu-class GST of 25 kDa from Taenia solium (Ts25GST), which was subsequently refined via all-atom MD simulations in explicit solvent to obtain a representative ensemble of conformations [3]. This refinement step is critical, as static single-structure docking may miss conformational flexibility that affects ligand binding.

Binding Site Identification

Putative binding sites are identified through a combination of geometric pocket detection and energy-based mapping. The SILCS (Site Identification by Ligand Competitive Saturation) methodology, which uses explicit solvent MD simulations to map the free energy of functional group binding, has been applied to Ts25GST to locate a binding site with low conservation relative to human GSTs [3]. This site-specific conservation analysis is essential for designing selective inhibitors; in the Ts25GST study, the identified pocket allowed virtual enrichment of compounds that subsequently showed 50–70% enzyme inhibition while reducing human mu-class GSTM1 activity by only 30–35% [3].

Virtual Screening and Docking

Virtual screening employs molecular docking algorithms to predict binding poses and estimate binding affinities. AutoDock Vina, a widely used open-source docking engine, has been applied to screen compound libraries against Leishmania TryR and GPDH [1]. In ensemble docking, multiple receptor conformations from MD trajectories are used to account for protein flexibility. The Ts25GST study employed ensemble docking against representative structures from MD simulations [3]. Docking scores are typically reported as predicted binding free energies (kcal/mol); for example, compound CID 6529858 showed a score of −8.9 kcal/mol against Leishmania GPDH, compared to −7.2 kcal/mol against human GPDH, yielding a parasite-favored difference of −1.7 kcal/mol [1].

ADMET Prediction

Candidate inhibitors must possess favorable pharmacokinetic and safety profiles. Computational ADMET tools (e.g., SwissADME, pkCSM) predict properties such as gastrointestinal absorption, blood-brain barrier penetration, cytochrome P450 inhibition, and toxicity endpoints including mutagenicity and hepatotoxicity [1, 2]. In the Leishmania study, ADMET screening narrowed a library to 41 drug-like candidates [1]. In the Theileria epidrug assessment, compounds such as SAHA, Trichostatin A, and BVT-948 were predicted to have favorable ADME/T characteristics, whereas others (Plumbagin, Methylstat, TCE-5003) showed potential mutagenic or hepatotoxic effects [2].

Molecular Dynamics Validation

MD simulations (typically 50–200 ns) are used to validate the stability of predicted protein-ligand complexes. Key metrics include root-mean-square deviation (RMSD) of backbone atoms, root-mean-square fluctuation (RMSF) of residues, and principal component analysis (PCA) of large-scale motions. In the Leishmania study, CID 6529859-GPDH complexes showed low backbone RMSD (approx. 0.25–0.40 nm), and eupatorin-TryR complexes had RMSD averaging 0.45 nm [1]. PCA indicated that ligand binding restricted global motions; for example, PC1 accounted for 27.38% of GPDH motion variance and 18.1% for TryR [1]. These metrics support stable binding and suggest that the inhibitors reduce protein flexibility.

Integrated Workflow: A Decision Tree

The following diagram represents the typical computational workflow for veterinary antiparasitic docking screening.

flowchart TD
    A[Target Selection], > B[Structure Prediction\n(AlphaFold / Homology Modeling)]
    B, > C[MD Refinement\n(Explicit Solvent)]
    C, > D[Binding Site Identification\n(SILCS / Pocket Detection)]
    D, > E[Compound Library\n(Commercial / Epigenetic / Natural)]
    E, > F[Ensemble Docking\n(AutoDock Vina)]
    F, > G[Selection by Docking Score\n& Conservation Filter]
    G, > H[ADMET Prediction\n(SwissADME / pkCSM)]
    H, > I[Filtered Hit List]
    I, > J[MD Validation\n(Stability, RMSD, PCA)]
    J, > K[Candidate Prioritization]
    K, > L[Experimental Testing\n(Enzyme Inhibition, Cell Assays)]

Case Studies in Veterinary Antiparasitic Screening

Helminths: Inhibition of Taenia solium Glutathione S-Transferase

The cestode Taenia solium causes cysticercosis in pigs and humans. Ts25GST, a mu-class enzyme, was targeted using a computational workflow that combined AlphaFold modeling, MD refinement, SILCS binding site mapping, and ensemble docking against a commercial compound library [3]. Two selective inhibitors, designated i11 and i15, were identified. Enzyme assays demonstrated 50–70% inhibition of Ts25GST activity with only 30–35% inhibition of human GSTM1, demonstrating selectivity [3]. Kinetic analysis revealed that i11 acts as a competitive inhibitor with respect to the substrate CDNB, whereas i15 is noncompetitive [3]. This study exemplifies how docking workflows can prioritize compounds with differential species selectivity.

Protozoa: Dual Targeting of Trypanothione Reductase and Glycerol-3-Phosphate Dehydrogenase in Leishmania

Leishmaniasis affects dogs, cats, and livestock in endemic regions. An integrated in silico platform using ADMET prediction, AutoDock Vina docking, and 100 ns MD simulations identified two lead compounds: CID 6529858 as a GPDH-focused scaffold (−8.9 kcal/mol) and eupatorin (CID 97214) as a dual-target inhibitor (TryR −7.5 kcal/mol, Leishmania GPDH −8.2 kcal/mol) [1]. Both exhibited favorable ADMET profiles, and MD showed stable trajectories with restricted global motions (PCA) [1]. The inclusion of human GPDH as a negative control provided an early selectivity assessment, critical for veterinary applications where host toxicity must be minimized.

Apicomplexa: Epidrug Screening Against Theileria annulata

Theileria annulata causes tropical theileriosis in cattle, with current treatments facing resistance. A library of 148 epigenetic inhibitors was screened computationally and experimentally against T. annulata-infected cells [2]. Molecular docking confirmed effective binding of active compounds (e.g., SAHA, Trichostatin A, BVT-948) to parasite orthologs of human epigenetic targets (HDAC, PRMT, SET domain). ADME/T predictions flagged three compounds as unsuitable, while SAHA, Trichostatin A, and BVT-948 showed promising characteristics and low predicted toxicity [2]. This study illustrates how docking workflows can repurpose epidrugs for veterinary antiparasitic applications.

Frequently Asked Questions

What is molecular docking and how is it applied in veterinary antiparasitic drug discovery?

Molecular docking is a computational technique that predicts the preferred orientation of a small molecule (ligand) when bound to a target protein (receptor) to form a stable complex [3, 1]. It estimates binding affinity and is used to rank candidate compounds from large libraries, thereby prioritizing those most likely to inhibit parasite-specific enzymes while sparing host orthologs.

How are target proteins selected for antiparasitic docking workflows?

Targets are chosen based on their essentiality for parasite survival and their divergence from host counterparts. Examples include GSTs in helminths, TryR in Leishmania, and epigenetic regulators in Theileria [3, 1, 2]. Structural data or high-quality models (e.g., from AlphaFold) must be available or generated.

What is ensemble docking and why is it important?

Ensemble docking uses multiple conformations of the receptor obtained from MD simulations rather than a single static structure. This approach accounts for protein flexibility and improves the enrichment of true binders [3]. In the Ts25GST study, ensemble docking against MD-derived conformations yielded selective inhibitors [3].

How is selectivity for parasite over host enzyme evaluated computationally?

Selectivity is assessed by docking the same compounds against the homologous host enzyme (e.g., human GST, human GPDH) and comparing docking scores [3, 1]. A favorable difference (Δscore) of at least 1.0–1.5 kcal/mol indicates potential selectivity. In the Ts25GST study, selective compounds were further confirmed in enzymatic assays [3].

What is the role of MD simulations after docking?

MD simulations validate that the predicted binding pose remains stable over time, monitoring RMSD and RMSF. They also provide insight into ligand-induced changes in protein dynamics via PCA [1]. Stable trajectories support the likelihood of true binding.

Can docking workflows identify compounds with dual-target activity?

Yes. Integrated workflows can screen compounds against multiple parasite targets simultaneously. In the Leishmania study, eupatorin showed favorable docking scores against both TryR and GPDH, suggesting dual-target potential [1].

What ADMET properties are most critical for veterinary antiparasitic compounds?

Key properties include high gastrointestinal absorption, low hepatotoxicity, and absence of mutagenicity. The Theileria epidrug study flagged hepatotoxic and mutagenic compounds (Plumbagin, Methylstat, TCE-5003) as unsuitable, while SAHA, Trichostatin A, and BVT-948 passed ADME/T filters [2].

How are computational predictions validated experimentally?

Enzyme inhibition assays (e.g., IC50 determination) and host cell cytotoxicity assays are the standard next steps. The Ts25GST study used a CDNB-based activity assay to confirm 50–70% inhibition [3]. Parasite viability assays in infected cell lines (as for T. annulata) provide additional validation [2].

References

[1] Alisaac A. In Silico Targeting of Trypanothione Reductase and Glycerol-3-Phosphate Dehydrogenase in Leishmania. Microorganisms. 2026. https://www.semanticscholar.org/paper/d09d3303825b976e62a88d4f4ffb6f601dd426e6

[2] Kamble S, Singh S, Suresh A, et al. Epidrugs: alternative chemotherapy targeting Theileria annulata schizont stage parasites. Microbiology Spectrum. 2024. https://www.semanticscholar.org/paper/597b822555a22739d519d3a9fdc4013c9372cdc3 *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[3] Sánchez-Juárez C, Flores-López R, Sánchez-Pérez LDC, et al. Discovery and Characterization of Two Selective Inhibitors for a Mu-Class Glutathione S-Transferase of 25 kDa from Taenia solium Using Computational and Bioinformatics Tools. Biomolecules. 2024. https://www.semanticscholar.org/paper/45edcddb6a4f77bb6260d20ea5e958fe6a5337a0